ARK Genomic Revolution ETF vs Franklin Resources, Inc. — how do they compare? ARK Genomic Revolution ETF trades at $44.36, while Franklin Resources, Inc. trades at $33.37 (market cap $16.95B). The key difference: Franklin Resources, Inc. pays a 3.96% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Franklin Resources, Inc. nearer its low. Which is the better fit depends on your goals.
| ARKG | BEN | |
|---|---|---|
Sector | Sector/Thematic | Financials |
52-Week High | $44.55 | $35.77 |
52-Week Low | $24.02 | $21.18 |
Market Cap | — | $16.95B |
Enterprise Value | — | $29.90B |
Dividend Yield | — | 3.96% |
Trailing returns across standard periods
Latest headlines on both assets
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →Franklin Resources provides investment services for individual and institutional investors. At the end of August 2022, Franklin had $1.388 trillion in managed assets, composed primarily of equity (32%), fixed-income (38%), multi-asset/balanced (10%) funds, alternatives (16%), and money market funds (4%). Distribution tends to be weighted more toward retail investors (49% of AUM) investors, as opposed to institutional (49%) and high-net-worth (2%) clients. Franklin is also one of the more global firms of the U.S.-based asset managers with more than 35% of its AUM invested in global/international strategies and 25% of managed assets sourced from clients domiciled outside the United States.
Read more on BEN →